XXII

XXII is a $2.65M market-cap tobacco micro-cap that fails the most basic test of a viable business: it cannot make its product profitably. Full-year 2025 gross margin was ~0.1%, and management's own MD&A discloses a gross LOSS of $3,137K in 2025 that actually WIDENED from a $2,400K loss in 2024 — selling more cartons destroys value. Revenue is in structural decline, falling -27.9% to $17.6M in FY2025 after $24.4M (2024) and $32.2M (2023); Q4 cartons sold dropped to 248 from 338 a year prior. Operating loss of -$11.6M on $17.6M of revenue (-65.8% operating margin) and negative operating cash flow of -$7.72M against just $7.15M of cash leave roughly one year of runway before another raise.

The capital structure is the tell. Shares outstanding fell -72.1% to 662K and diluted EPS is -$52.87 — the artifacts of repeated reverse stock splits (MD&A confirms 'prior reverse stock splits'). The -$399M accumulated deficit against $15.8M of equity means shareholders have funded nearly $400M of cumulative losses, and the '292.8%' jump in equity plus '61.7%' rise in cash came from dilution/capital raises, not operations. The balance sheet looks 'clean' only because debt was wiped out by issuing stock; the pattern of split-and-dilute is precisely what makes any per-share target meaningless here.